WAM
PTIXW

Warberg Asset Management’s Protagenic Therapeutics Warrant PTIXW Stock Holding History

Warberg Asset Management’s Portfolio PTIXW Stock Details PTIXW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-170,242
Closed -$1.28K – 208
2025
Q1 		$1.28K Hold
170,242
– – ﹤0.01% 185
2024
Q4 		$1.04K Sell
170,242
-6,954
-4% -$62 ﹤0.01% 192
2024
Q3 		$2.11K Hold
177,196
– – ﹤0.01% 192
2024
Q2 		$1.45K Hold
177,196
– – ﹤0.01% 208
2024
Q1 		$5.74K Hold
177,196
– – ﹤0.01% 178
2023
Q4 		$1.56K Hold
177,196
– – ﹤0.01% 207
2023
Q3 		$5.32K Hold
177,196
– – ﹤0.01% 198
2023
Q2 		$5.94K Hold
177,196
– – ﹤0.01% 193
2023
Q1 		$4.29K Hold
177,196
– – ﹤0.01% 223
2022
Q4 		$7.26K Sell
177,196
-108,301
-38% -$3.98K ﹤0.01% 216
2022
Q3 		$12K Sell
285,497
-42,726
-13% -$3.32K ﹤0.01% 226
2022
Q2 		$49K Sell
328,223
-33,843
-9% -$4.38K 0.01% 148
2022
Q1 		$78K Buy
362,066
+180,532
+99% +$48.3K 0.01% 140
2021
Q4 		$69K Sell
181,534
-183,257
-50% -$73.7K 0.01% 141
2021
Q3 		$143K Sell
364,791
-999
-0.3% -$526 0.02% 118
2021
Q2 		$260K Buy
+365,790
New +$168K 0.05% 103

Other funds holding PTIXW

CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Warberg Asset Management's PTIXW Position: Q2 2025 in Review

Warberg Asset Management sold out of Protagenic Therapeutics Warrant (PTIXW) in Q2 2025, closing a stake of 170,242 shares — an estimated $1.28K sold.

Warberg Asset Management first reported a position in PTIXW in Q2 2021 and held it in 16 quarters. The position peaked at $260K in Q2 2021. 4 funds tracked by Wall St. Rank hold PTIXW as of Q2 2025.

  • Warberg Asset Management reported no remaining Protagenic Therapeutics Warrant position as of Q2 2025 after selling out during the quarter.
  • Warberg Asset Management sold 170,242 Protagenic Therapeutics Warrant shares in Q2 2025, an estimated $1.28K.
  • Warberg Asset Management first reported a position in Protagenic Therapeutics Warrant in Q2 2021 and held it in 16 quarters.
  • Warberg Asset Management's Protagenic Therapeutics Warrant position peaked at $260K in Q2 2021.
  • 4 funds tracked by Wall St. Rank held Protagenic Therapeutics Warrant as of Q2 2025.

Based on Warberg Asset Management's 13F filing for Q2 2025, filed 12 Aug 2025.